Fincor 10mg Tablet 10pcs

Composition

FINERENONE 

Dosage & Administration

• Starting Dosage: Begin with 10 mg or 20 mg orally once daily, depending on eGFR and serum potassium levels. After 4 weeks, adjust to the target dose of 20 mg once daily, considering eGFR and serum potassium.
  • eGFR ≥60 mL/min/1.73 m²: Start with 20 mg once daily.
  • eGFR 25 to <60 mL/min/1.73 m²: Start with 10 mg once daily.
  • eGFR <25 mL/min/1.73 m²: Not recommended.
• Administration: Tablets can be taken with or without food. For patients who cannot swallow tablets, they can be crushed and mixed with water or soft foods.

Side Effect

• Common adverse reactions (≥ 1% of patients) include hyperkalemia, hypotension, and hyponatremia.

Monitoring and Dose Adjustment

• Measure serum potassium 4 weeks after starting treatment or adjusting the dose, and adjust accordingly. If potassium levels are >4.8 to 5.0 mEq/L, consider additional monitoring and dosage adjustments based on clinical judgment.
• For missed doses, take them as soon as possible on the same day, or skip it if it is too late, then continue with the next dose as scheduled.

Interactions

• Strong CYP3A4 Inhibitors: Avoid using Finerenone with strong CYP3A4 inhibitors due to increased exposure and risk of adverse reactions. Grapefruit and grapefruit juice should also be avoided.
• Moderate and Weak CYP3A4 Inhibitors: Concomitant use may increase Finerenone exposure. Monitor serum potassium and adjust the dose as necessary.
• Strong and Moderate CYP3A4 Inducers: Avoid these as they may reduce Finerenone efficacy by decreasing exposure.

Contraindications

• Strong CYP3A4 Inhibitors: Avoid use.
• Adrenal Insufficiency: Contraindicated in patients with this condition.

Use in Special Populations

• Pediatric: Safety and efficacy not established in those under 18.
• Geriatric: No differences in safety or efficacy were observed in older patients. No dose adjustment is needed.
• Hepatic Impairment: Avoid severe hepatic impairment. No dosage adjustment for mild to moderate impairment, but consider additional monitoring.

Overdose Effects

• Symptoms: Primarily hyperkalemia. Discontinue Finerenone and initiate standard hyperkalemia treatment. Hemodialysis is unlikely to be effective.

Pregnancy & Lactation

• Pregnancy: Insufficient data on risks. Animal studies show developmental toxicity at high exposures. Use only if needed.
• Lactation: No data on human milk. Animal studies suggest that Finerenone is present in milk and may affect infants. Avoid breastfeeding during treatment and for 1 day after.

Precautions & Warnings

• Hyperkalemia: Monitor serum potassium and eGFR before starting and during treatment. Avoid initiating if potassium >5.0 mEq/L and adjust doses as needed.

Storage Conditions

• Store below 30°C, away from light and moisture. Keep out of reach of children.

Disposal

Discard any unused, expired medicine properly. Do not flush the medicine.